» Articles » PMID: 27124799

Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia

Overview
Journal J Med Chem
Specialty Chemistry
Date 2016 Apr 29
PMID 27124799
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

Fragment-based drug discovery (FBDD) is well suited for discovering both drug leads and chemical probes of protein function; it can cover broad swaths of chemical space and allows the use of creative chemistry. FBDD is widely implemented for lead discovery in industry but is sometimes used less systematically in academia. Design principles and implementation approaches for fragment libraries are continually evolving, and the lack of up-to-date guidance may prevent more effective application of FBDD in academia. This Perspective explores many of the theoretical, practical, and strategic considerations that occur within FBDD programs, including the optimal size, complexity, physicochemical profile, and shape profile of fragments in FBDD libraries, as well as compound storage, evaluation, and screening technologies. This compilation of industry experience in FBDD will hopefully be useful for those pursuing FBDD in academia.

Citing Articles

Thermal Titration Molecular Dynamics: The Revenge of the Fragments.

Pavan M, Menin S, Dodaro A, Novello G, Cavastracci Strascia C, Sturlese M J Chem Inf Model. 2025; 65(3):1492-1513.

PMID: 39835670 PMC: 11815869. DOI: 10.1021/acs.jcim.4c01681.


Fragmenstein: predicting protein-ligand structures of compounds derived from known crystallographic fragment hits using a strict conserved-binding-based methodology.

Ferla M, Sanchez-Garcia R, Skyner R, Gahbauer S, Taylor J, von Delft F J Cheminform. 2025; 17(1):4.

PMID: 39806443 PMC: 11731148. DOI: 10.1186/s13321-025-00946-0.


Robust proteome profiling of cysteine-reactive fragments using label-free chemoproteomics.

Biggs G, Cawood E, Vuorinen A, McCarthy W, Wilders H, Riziotis I Nat Commun. 2025; 16(1):73.

PMID: 39746958 PMC: 11697256. DOI: 10.1038/s41467-024-55057-5.


A review of the known MTA-cooperative PRMT5 inhibitors.

Hu M, Chen X RSC Adv. 2024; 14(53):39653-39691.

PMID: 39691229 PMC: 11650783. DOI: 10.1039/d4ra05497k.


Mapping protein binding sites by photoreactive fragment pharmacophores.

Abranyi-Balogh P, Bajusz D, Orgovan Z, Keeley A, Petri L, Peczka N Commun Chem. 2024; 7(1):168.

PMID: 39085342 PMC: 11292009. DOI: 10.1038/s42004-024-01252-w.